DFM Platform

Capability

Trince Laser Photoporation For Europes

Trince Laser Photoporation for Europes: what does the DFM Analysis cover, and why does it matter for European defence?

Trince is a Belgian deep-tech spin-off that has emerged from Ghent University’s biophotonics research community. The company is pioneering a laser-based method for inserting genetic material into living cells, offering…

Full figures, sources and the complete assessment are in the report — Read the full DFM Analysis →

Part of our Research, Universities & Deep Tech and Policy, Procurement & Institutions coverage →

Platform publication · DFM Analysis report · 2026-07-08

Trince is a Belgian deep-tech spin-off that has emerged from Ghent University’s biophotonics research community. The company is pioneering a laser-based method for inserting genetic material into living cells, offering a gentler alternative to traditional gene delivery techniques. Its proprietary LumiPore technology uses ultrashort laser pulses and custom-designed nanoparticles to temporarily open pores in cell membranes, allowing DNA, RNA, or other therapeutic molecules to enter without harming the cells. This innovation addresses a crucial bottleneck in cell therapy manufacturing: how to genetically modify patient cells efficiently while preserving their viability and function.

Founded in late 2021 in Ghent, Trince has quickly gained recognition in the biotech industry for its novel approach. In 2024 it won Nature’s Spinoff Prize, underscoring the broad potential of its platform. The company’s vision aligns with Europe’s drive for technological sovereignty in critical health and defense-related domains, positioning Trince as a promising contributor to European strategic autonomy in biotechnology. Trince (Trince BV) is an academic deep-tech spin-off founded in Belgium (Ghent) in 2021 [1] .

It specializes in laser photoporation technology (branded LumiPore ) for intracellular delivery, aligning with European Emerging Disruptive Technology (EDT) priorities in Biotechnology & Human Enhancement . Trince’s platform uses laser-activated nanoparticles to achieve high-efficiency, non-viral gene delivery into cells, a capability with dual-use relevance in advanced therapies and bio-defense. The company’s innovations bolster European strategic autonomy by offering a home-grown alternative to U.S. or Chinese gene-editing tools and viral vector suppliers [2] [3] . Its technology is being developed with EU support (e.g. a €2.5 million EIC Transition grant) and in collaboration with European partners [4] [5] .

By enabling safer, faster modification of cells (e.g. for CAR-T cancer therapies), Trince contributes to Europe’s interoperable defense-health capabilities – enhancing military medical readiness and resilience.

Key takeaways

  • Founded in late 2021 in Ghent, Trince has quickly gained recognition in the biotech industry for its novel approach.
  • It specializes in laser photoporation technology (branded LumiPore ) for intracellular delivery, aligning with European Emerging Disruptive Technology (EDT) priorities in Biotechnology & Human Enhancement .
  • By enabling safer, faster modification of cells (e.g.

Continue with the full evidence

This public thread is the short analytical version. The full DFM Analysis report adds the underlying figures and data, the complete source base, and the full procurement & capital-market assessment behind this summary.

Annual Professional unlocks the complete archive and DFM Intelligence (2,200+ company profiles) — See plans →

Original DFM analysis

Trince Laser Photoporation For Europes

Type DFM Analysis report
Published 2026-07-08 (Platform publication)
Access

FAQ

What is Trince Laser Photoporation For Europes?

The company is pioneering a laser-based method for inserting genetic material into living cells, offering a gentler alternative to traditional gene delivery techniques.

Why does Trince Laser Photoporation For Europes matter for European defence?

The company’s vision aligns with Europe’s drive for technological sovereignty in critical health and defense-related domains, positioning Trince as a promising contributor to European strategic autonomy in biotechnology.

Topics Strategic Autonomy #strategic-autonomy

Professional comments

Join the discussion on DFM Analysis.

Read & subscribe on DFM Analysis →

Related DFM Platform threads

Explore this category Strategic Autonomy

Professional requests (internal interest signal — not a marketplace; nothing is charged or promised)

Defence Finance Monitor is an analytical and informational product. It does not constitute investment advice, financial advice or a recommendation to buy or sell securities. Subscriptions run on DFM Analysis. Payments for Professional Packs are processed securely by Stripe at checkout.